tbuckley/cabot-search huggingface dataset:
Role of adenosine in the depolarization of hypoxic hamster diaphragm membrane in vitro.
Authors: S A Esau
Journal: American Journal of Respiratory and Critical Care Medicine (1994)

The resting membrane potential of in vitro hamster diaphragm muscle fibers is depolarized on exposure to hypoxia. It was hypothesized that this depolarization was mediated by adenosine. It was predicted that the treatment of well-oxygenated hamster diaphragm muscle strips in vitro with adenosine or adenosine agonists would depolarize the diaphragm fiber membrane. Furthermore, resting membrane potential of hypoxic diaphragm fibers would be repolarized by (1) the removal of adenosine by the enzyme adenosine deaminase (ADA), or (2) the addition of an adenosine antagonist, BW A1433. Adenosine (10(-4) M) depolarized the membrane by 8 +/- 1 mV (p < 0.001). The adenosine agonist cyclopentyladenosine, which has predominantly A1 receptor affinity, depolarized the membrane from -75.4 +/- 5.6 mV to -68.9 +/- 5.7 mV (p < 0.001). The A2 adenosine receptor agonist 5'-N-ethylcarboxamide adenosine did not cause a significant depolarization. The addition of ADA (2 unit/ml) to hypoxic muscle returned the resting membrane potential to that of well-oxygenated fibers, p < 0.001 versus hypoxia. BW A1433 (3 x 10(-7)) also restored the membrane potential of hypoxic muscle fibers from -72 +/- 1 mV to -79 +/- 1 mV (p < 0.001). These observations suggest that adenosine via the A1 adenosine receptor mediates the hypoxic depolarization of in vitro hamster diaphragm muscle. A direct effect of adenosine on muscle membrane has not been described previously.
Special Experience and Service
Authors: I. M. Scott
Journal: BMJ (1966)

What I would suggest would be: (1) a standard capitatien fee (or remuneration) at entry and for the first five years (the " basic " fee).(2) A 10%/ increase after five years of service.(3) A further 10% (of the basic) increase each five years thereafter, so that after 25 years' service the general practitioner was on a maximum of 150% of the basic rate.This I feel would be the fairest way of arranging things all round.It would at least, to a certain extent, look after the general practitioner who was beginning to "feel his years," and also one living in an area where the population was tending to diminish.-Iam, etc.,
Adaptive Evolution and Effective Population Size in Wild House Mice
Authors: M. Phifer-Rixey, F. Bonhomme, P. Boursot, G. A. Churchill, J. Pialek, P. K. Tucker, M. W. Nachman
Journal: Molecular Biology and Evolution (2012)

Estimates of the proportion of amino acid substitutions that have been fixed by selection (α) vary widely among taxa, ranging from zero in humans to over 50% in Drosophila. This wide range may reflect differences in the efficacy of selection due to differences in the effective population size (N(e)). However, most comparisons have been made among distantly related organisms that differ not only in N(e) but also in many other aspects of their biology. Here, we estimate α in three closely related lineages of house mice that have a similar ecology but differ widely in N(e): Mus musculus musculus (N(e) ∼ 25,000-120,000), M. m. domesticus (N(e) ∼ 58,000-200,000), and M. m. castaneus (N(e) ∼ 200,000-733,000). Mice were genotyped using a high-density single nucleotide polymorphism array, and the proportions of replacement and silent mutations within subspecies were compared with those fixed between each subspecies and an outgroup, Mus spretus. There was significant evidence of positive selection in M. m. castaneus, the lineage with the largest N(e), with α estimated to be approximately 40%. In contrast, estimates of α for M. m. domesticus (α = 13%) and for M. m. musculus (α = 12 %) were much smaller. Interestingly, the higher estimate of α for M. m. castaneus appears to reflect not only more adaptive fixations but also more effective purifying selection. These results support the hypothesis that differences in N(e) contribute to differences among species in the efficacy of selection.
The Impact of a One-Dose versus Two-Dose Oral Cholera Vaccine Regimen in Outbreak Settings: A Modeling Study
Authors: Andrew S. Azman, Francisco J. Luquero, Iza Ciglenecki, Rebecca F. Grais, David A. Sack, Justin Lessler
Journal: PLoS Medicine (2015)

Background In 2013, a stockpile of oral cholera vaccine (OCV) was created for use in outbreak response, but vaccine availability remains severely limited. Innovative strategies are needed to maximize the health impact and minimize the logistical barriers to using available vaccine. Here we ask under what conditions the use of one dose rather than the internationally licensed two-dose protocol may do both. Methods and Findings Using mathematical models we determined the minimum relative single-dose efficacy (MRSE) at which single-dose reactive campaigns are expected to be as or more effective than two-dose campaigns with the same amount of vaccine. Average one- and two-dose OCV effectiveness was estimated from published literature and compared to the MRSE. Results were applied to recent outbreaks in Haiti, Zimbabwe, and Guinea using stochastic simulations to illustrate the potential impact of one- and two-dose campaigns. At the start of an epidemic, a single dose must be 35%–56% as efficacious as two doses to avert the same number of cases with a fixed amount of vaccine (i.e., MRSE between 35% and 56%). This threshold decreases as vaccination is delayed. Short-term OCV effectiveness is estimated to be 77% (95% CI 57%–88%) for two doses and 44% (95% CI −27% to 76%) for one dose. This results in a one-dose relative efficacy estimate of 57% (interquartile range 13%–88%), which is above conservative MRSE estimates. Using our best estimates of one- and two-dose efficacy, we projected that a single-dose reactive campaign could have prevented 70,584 (95% prediction interval [PI] 55,943–86,205) cases in Zimbabwe, 78,317 (95% PI 57,435–100,150) in Port-au-Prince, Haiti, and 2,826 (95% PI 2,490–3,170) cases in Conakry, Guinea: 1.1 to 1.2 times as many as a two-dose campaign. While extensive sensitivity analyses were performed, our projections of cases averted in past epidemics are based on severely limited single-dose efficacy data and may not fully capture uncertainty due to imperfect surveillance data and uncertainty about the transmission dynamics of cholera in each setting. Conclusions Reactive vaccination campaigns using a single dose of OCV may avert more cases and deaths than a standard two-dose campaign when vaccine supplies are limited, while at the same time reducing logistical complexity. These findings should motivate consideration of the trade-offs between one- and two-dose campaigns in resource-constrained settings, though further field efficacy data are needed and should be a priority in any one-dose campaign.
Discovery and Development of Therapeutic Aptamers
Authors: P.R. Bouchard, R.M. Hutabarat, K.M. Thompson
Journal: The Annual Review of Pharmacology and Toxicology (2010)

Therapeutic aptamers are single-stranded structured oligonucleotides that bind to protein targets with high affinity and specificity and modulate protein function. Aptamers are discovered by iterative rounds of selection for binding to the target protein, partitioning, and amplification of binding clones from a diverse starting library (SELEX). Postselection optimization of clones using chemical modification is directed at improving affinity, potency, and metabolic stability. A key attribute of therapeutic aptamers is the ability to tailor the pharmacokinetic profile by modulating the degree of metabolic stability and modulating renal clearance and rate of distribution by conjugation to various sizes of polyethylene glycol (PEG). In toxicology studies, therapeutic aptamers have been largely devoid of the previously reported oligonucleotide class effects of immune stimulation, complement activation, and anticoagulation; and the principal finding is the histologically visible accumulation of drug-related material in mononuclear phagocytes, a finding generally not considered an adverse effect. Good safety margins between the pharmacologically effective dose and toxicologically established no-adverse-effect levels have been observed consistently. There are presently seven aptamers either on the market or in clinical trials, but there is still much to be demonstrated in terms of chronic systemic use to fully realize the potential of this promising new class of drugs.
Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12.
Authors: C M Bacon, D W McVicar, J R Ortaldo, R C Rees, J J O'Shea, J A Johnston
Journal: The Journal of Experimental Medicine (1995)

Interleukin (IL-12) has many effects on the function of natural killer and T cells, and is important in the control of cell-mediated immunity. IL-2 and IL-12 display many similar activities, yet each also induces a distinct set of responses. A human IL-12 receptor subunit has recently been cloned and, like the IL-2R beta and IL-2R gamma, is a member of the hematopoietic receptor superfamily; however, the molecular mechanisms of IL-12 action are unknown. In this report we show that IL-12 and IL-2 induce tyrosine phosphorylation of distinct members of the Janus (JAK) family of protein tyrosine kinases in human T lymphocytes. IL-12, but not IL-2, stimulates the tyrosine phosphorylation of TYK2 and JAK2, whereas JAK1 and JAK3, which are phosphorylated in response to IL-2, are not phosphorylated after IL-12 treatment. The use of distinct but related JAK family tyrosine kinases by IL-12 and IL-2 may provide a biochemical basis for their different biological activities.
Adolescent Irritability: Phenotypic Associations and Genetic Links With Depressed Mood
Authors: Argyris Stringaris, Helena Zavos, Ellen Leibenluft, Barbara Maughan, Thalia C. Eley
Journal: American Journal of Psychiatry (2011)

Irritability has been proposed to underlie the developmental link between oppositional problems and depression. Little is known, however, about the genetic and environmental influences on irritability and its overlap with depression. Drawing on the notion of "generalist genes" (genes of general effect that underlie phenotypic overlap between disorders), the authors test the hypothesis that the association between irritability and depression is accounted for by genetic factors.Data from the G1219 study, a U.K. twin/sibling sample (N=2,651), were used in a cross-sectional and longitudinal design. The irritable and headstrong/hurtful dimensions of oppositional behavior were derived using factor analysis. Regression was used to estimate the association between depression and delinquency. Multivariate genetic analyses were used to estimate the genetic overlaps between the two components of oppositionality (irritability and headstrong/hurtful behaviors) and depression and delinquency.Irritability showed a significantly stronger phenotypic relationship with depression than with delinquency, whereas headstrong/hurtful behaviors were more strongly related to delinquency than to depression. In multivariate genetic analyses, the genetic correlation between irritability and depression (r(A)=0.70, 95% CI=0.59-0.82) was significantly higher than that between headstrong/hurtful behaviors and depression (r(A)=0.46, 95% CI=0.36-0.57); [corrected] conversely, the genetic correlation between headstrong/hurtful behaviors and delinquency (r(A)=0.80, 95% CI=0.72-0.86) was significantly higher than that between irritability and delinquency (r(A)=0.57, 95% CI=0.45-0.69). [corrected].These findings are consistent with the theory that genes with general effects underlie the relationship between irritability and depression.
Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer
Authors: Mitch Dowsett, Anita K. Dunbier
Journal: Clinical Cancer Research (2008)

Abstract The era of personalized medicine is likely to see an escalation in the use of biomarkers to ensure breast cancer patients receive optimal treatment. A combination of prognostic and predictive biomarkers should enable better quantification of the residual risk faced by patients and indicate the potential value of additional treatment. Established biomarkers such as estrogen receptor and progesterone receptor already play a significant role in the selection of patients for endocrine therapy. Human epidermal growth factor receptor 2 (HER2) is recognized as a strong predictor of response to trastuzumab whereas, more recently, the role of estrogen receptor and HER2 as negative and positive indicators for chemotherapy has also been explored. Ki67 has traditionally been recognized as a modest prognostic factor, but recent neoadjuvant studies suggest that on-treatment measurement may be a more effective predictor of treatment efficacy for both endocrine treatment and chemotherapy. The last decade has seen the emergence of numerous multigene expression profiles that aim to outdo traditional predictive and prognostic factors. The Oncotype DX assay and the MammaPrint profile are currently undergoing prospective clinical trials to clearly define their role. Other gene expression–based assays also show potential but are yet to be tested clinically. Rigorous comparison of these emerging markers with current treatment selection criteria will be required to determine whether they offer significant benefit to justify their use.
A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression
Authors: George Giotopoulos, Louise van der Weyden, Hikari Osaki, Alistair G. Rust, Paolo Gallipoli, Eshwar Meduri, Sarah J. Horton, Wai-In Chan, Donna Foster, Rab K. Prinjha, John E. Pimanda, Daniel G. Tenen, George S. Vassiliou, Steffen Koschmieder, David J. Adams, Brian J.P. Huntly
Journal: The Journal of Experimental Medicine (2015)

The introduction of highly selective ABL-tyrosine kinase inhibitors (TKIs) has revolutionized therapy for chronic myeloid leukemia (CML). However, TKIs are only efficacious in the chronic phase of the disease and effective therapies for TKI-refractory CML, or after progression to blast crisis (BC), are lacking. Whereas the chronic phase of CML is dependent on BCR-ABL, additional mutations are required for progression to BC. However, the identity of these mutations and the pathways they affect are poorly understood, hampering our ability to identify therapeutic targets and improve outcomes. Here, we describe a novel mouse model that allows identification of mechanisms of BC progression in an unbiased and tractable manner, using transposon-based insertional mutagenesis on the background of chronic phase CML. Our BC model is the first to faithfully recapitulate the phenotype, cellular and molecular biology of human CML progression. We report a heterogeneous and unique pattern of insertions identifying known and novel candidate genes and demonstrate that these pathways drive disease progression and provide potential targets for novel therapeutic strategies. Our model greatly informs the biology of CML progression and provides a potent resource for the development of candidate therapies to improve the dismal outcomes in this highly aggressive disease.
Effect of bone-like layer growth from culture medium on adherence of osteoblast-like cells
Authors: Takashi Kizuki, Masataka Ohgaki, Mihoko Katsura, Satoshi Nakamura, Kazuaki Hashimoto, Yoshitomo Toda, Shigekazu Udagawa, Kimihiro Yamashita
Journal: Biomaterials (2002)
Different Molecular Profiles Characterize Well-Differentiated Endocrine Tumors and Poorly Differentiated Endocrine Carcinomas of the Gastroenteropancreatic Tract
Authors: Daniela Furlan, Roberta Cerutti, Silvia Uccella, Stefano La Rosa, Elena Rigoli, Anna Genasetti, Carlo Capella
Journal: Clinical Cancer Research (2004)

Abstract Purpose: The molecular pathogenesis of gastroenteropancreatic endocrine tumors (ETs) is still largely unknown. The purpose of this work was a molecular characterization of 38 gastroenteropancreatic ETs with respect to the primary site and to the morphofunctional profile, pointing out useful diagnostic or prognostic molecular markers. Experimental Design: Twenty-four well-differentiated ETs or carcinomas (WDET/Cs; 11 pancreatic, 3 gastric, and 10 intestinal) and 14 poorly differentiated endocrine carcinomas (1 pancreatic, 6 gastric, and 7 colorectal) were microallelotyped using 38 polymorphic microsatellite markers covering chromosomes 1, 3, 5q, 6, 11, 17, and 18. Results: Regardless of the primary site, a significantly higher percentage of allelic imbalances (AIs) was observed in poorly differentiated endocrine carcinomas than in WDET/Cs (P = 0.012), except for 3 of 8 nonfunctioning pancreatic endocrine tumors and 1 colorectal WDEC, exhibiting multiple AIs on chromosomes 1, 3, 6, and 11. A strong positive correlation between AI percentage and Ki-67 proliferation index was detected considering both the whole series of ETs (P = 0.004) and the group of WDET/Cs alone (P = 0.011). The survival analysis showed a positive correlation between low percentage of AI and longer survival (P = 0.01). No recurrent AIs at specific chromosomal regions were identifiable with respect to the primary site. Conclusions: The malignant progression of endocrine tumors seems to be associated with complex allelotypes and chromosomal instability. Although no specific molecular markers of malignancy can be defined with certainty, the ploidy status and the degree of chromosomal derangements appear to be the most informative genetic factors with prognostic significance.
CpG-DNA derived from sera in systemic lupus erythematosus enhances ICAM-1 expression on endothelial cells
Authors: M Miyata
Journal: Annals of the Rheumatic Diseases (2001)

To examine the effect of transfection of oligodeoxynucleotides (ODNs) containing a CpG motif (CpG-ODN), of which the sequence was derived from circulating DNA in the sera of patients with systemic lupus erythematosus (SLE), on the expression of intercellular adhesion molecule-1 (ICAM-1) and synthesis of mRNA for proinflammatory cytokines and ICAM-1 in human umbilical vein endothelial cells (EC).A CpG-ODN or a control analogue, GpC-ODN, was transfected into EC. ICAM-1 expression was examined by flow cytometry, and expression of mRNA in EC encoding interleukin 1 (IL1), IL6, IL8, tumour necrosis factor alpha (TNFalpha), interferon gamma (IFNgamma), and ICAM-1 was examined by semiquantitative reverse transcriptase-polymerase chain reaction.The CpG-ODN augmented the expression of ICAM-1 on EC determined by flow cytometry and increased mRNA levels of IL6, IL8, TNFalpha, IFNgamma, and ICAM-1, but the GpC-ODN did not.Synthesised DNA, with a sequence corresponding to that of the fragment containing the CpG motif, in sera of patients with SLE was found to enhance ICAM-1 expression on EC, suggesting the participation of circulating DNA fragments in the pathogenesis of vasculitis in SLE.
Binding of Carcinogenic Halogenated Hydrocarbons to Cell Macromolecules2
Authors: Sipra Banerjee, Benjamin L. van Duuren
Journal: JNCI Journal of the National Cancer Institute (1979)

Ethylene dibromide (EDB), a known stomach carcinogen, and ethylene dichloride (EDC), which is carcinogenic to the liver, have been shown in in vitro experiments to bind covalently to stomach and hepatic microsomal proteins and to salmon sperm DNA. The binding of EDB or EDC with proteins was not significant when denatured microsomes were used or when DNA was used in the absence of microsomes. The binding of EDB to these macromolecules was augmented with increasing concentrations of microsomes. SKF-525A, an inhibitor of the microsomal metabolism of various substrates, significantly inhibited the binding of EDB to protein and DNA. These findings suggest that metabolic activation of EDB and EDC is required for their covalent binding to macromolecules. Glutathione and 1-methyl-2-mercaptoimidazole markedly decreased the binding of EDB, which indicated that a reactive electrophilic intermediate(s) of EDB is (are) involved in the binding. The binding of EDC to liver proteins of (C57BL/6 × C3H/He)F1 mice, which are susceptible to liver tumor induction by EDC and to DNA, was significantly higher than the corresponding binding for Osborne-Mendel rats, a species not susceptible to liver tumor induction by this compound.
Estimates and Projections of Value of Life Lost From Cancer Deaths in the United States
Authors: K. Robin Yabroff, Cathy J. Bradley, Angela B. Mariotto, Martin L. Brown, Eric J. Feuer
Journal: JNCI Journal of the National Cancer Institute (2008)

Value-of-life methods are increasingly used in policy analyses of the economic burden of disease. The purpose of this study was to estimate and project the value of life lost from cancer deaths in the United States.We estimated and projected US age-specific mortality rates for all cancers and for 16 types of cancer in men and 18 cancers in women in the years 2000-2020 and applied them to US population projections to estimate the number of deaths in each year. Cohort life tables were used to calculate the remaining life expectancy in the absence of cancer deaths-the person-years of life lost (PYLL). We used a willingness-to-pay approach in which the value of life lost due to cancer death was calculated by multiplying PYLL by an estimate of the value of 1 year of life ($150,000). We performed sensitivity analyses for female breast, colorectal, lung, and prostate cancers using varying assumptions about future cancer mortality rates through the year 2020.The value of life lost from all cancer deaths in the year 2000 was $960.6 billion; lung cancer alone represented more than 25% of this value. Projections for the year 2020 with current cancer mortality rates showed a 53% increase in the total value of life lost ($1472.5 billion). Projected annual decreases of cancer mortality rates of 2% reduced the expected value of life lost in the year 2020 from $121.0 billion to $80.7 billion for breast cancer, $140.1 billion to $93.5 billion for colorectal cancer, from $433.4 billion to $289.4 billion for lung cancer, and from $58.4 billion to $39.0 billion for prostate cancer.Estimated value of life lost due to cancer deaths in the United States is substantial and expected to increase dramatically, even if mortality rates remain constant, because of expected population changes. These estimates and projections may help target investments in cancer control strategies to tumor sites that are likely to result in the greatest burden of disease and to interventions that are the most cost-effective.